Type 2 Diabetes Mellitus: From Metabolic Dysfunction Syndrome to Precision Prevention and Targeted Therapy

Abstract

Type 2 diabetes mellitus (T2DM) remains a prevalent metabolic disorder worldwide, continuously imposinga substantial clinical and socioeconomic burden. Traditionally viewed as a glucose-centered diseasecharacterized by hyperglycemia driven by insulin resistance and pancreatic beta-cell dysfunction, recentevidence clearly indicates that hyperglycemia is merely a downstream manifestation of broader metabolicabnormalities. Advances in molecular biology, immunometabolism, and systems biology have facilitated theemergence of Metabolic Dysfunction Syndrome (MDS) as a comprehensive framework for understandingT2DM pathogenesis. This review summarizes the interconnected roles of insulin resistance, adipose tissuedysfunction, ectopic lipid accumulation, chronic low-grade inflammation, oxidative stress, mitochondrialdysfunction, progressive beta-cell failure, and inter-organ crosstalk in disease progression. Furthermore, weextensively discuss the vital clinical implications of this paradigm shift, highlighting the critical importance ofearly risk stratification, prescreening, timely diagnosis, and personalized therapeutic algorithms extendingbeyond mere glycemic control. Emerging pharmacological therapies with cardiometabolic and renoprotectivebenefits, combined with holistic lifestyle interventions, firmly support a vital transition fromreactive glucose-lowering strategies to proactive disease-modifying approaches targeting underlyingmetabolic dysfunction. Ultimately, adopting the MDS framework provides a highly integrated understandingof T2DM, directly offering unprecedented opportunities for precision prevention, individualized treatment,and improved long-term clinical outcomes globally for all affected patients.